Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 15 05 2020
accepted: 28 09 2020
revised: 02 09 2020
pubmed: 10 10 2020
medline: 10 4 2021
entrez: 9 10 2020
Statut: ppublish

Résumé

Autosomal-dominant leukodystrophy (ADLD) is a rare fatal neurodegenerative disorder with overexpression of the nuclear lamina component, Lamin B1 due to LMNB1 gene duplication or deletions upstream of the gene. The molecular mechanisms responsible for driving the onset and development of this pathology are not clear yet. Vacuolar demyelination seems to be one of the most significant histopathological observations of ADLD. Considering the role of oligodendrocytes, astrocytes, and leukemia inhibitory factor (LIF)-activated signaling pathways in the myelination processes, this work aims to analyze the specific alterations in different cell populations from patients with LMNB1 duplications and engineered cellular models overexpressing Lamin B1 protein. Our results point out, for the first time, that astrocytes may be pivotal in the evolution of the disease. Indeed, cells from ADLD patients and astrocytes overexpressing LMNB1 show severe ultrastructural nuclear alterations, not present in oligodendrocytes overexpressing LMNB1. Moreover, the accumulation of Lamin B1 in astrocytes induces a reduction in LIF and in LIF-Receptor (LIF-R) levels with a consequential decrease in LIF secretion. Therefore, in both our cellular models, Jak/Stat3 and PI3K/Akt axes, downstream of LIF/LIF-R, are downregulated. Significantly, the administration of exogenous LIF can partially reverse the toxic effects induced by Lamin B1 accumulation with differences between astrocytes and oligodendrocytes, highlighting that LMNB1 overexpression drastically affects astrocytic function reducing their fundamental support to oligodendrocytes in the myelination process. In addition, inflammation has also been investigated, showing an increased activation in ADLD patients' cells.

Identifiants

pubmed: 33034697
doi: 10.1007/s00018-020-03661-1
pii: 10.1007/s00018-020-03661-1
pmc: PMC8004488
doi:

Substances chimiques

Inflammation Mediators 0
Lamin Type B 0
Leukemia Inhibitory Factor 0
Reactive Oxygen Species 0
Receptors, OSM-LIF 0
Hydrogen Peroxide BBX060AN9V

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2781-2795

Références

AJNR Am J Neuroradiol. 2006 Apr;27(4):904-11
pubmed: 16611789
Physiol Rev. 2018 Jan 1;98(1):239-389
pubmed: 29351512
Nucleus. 2013 Jul-Aug;4(4):283-90
pubmed: 23873483
Exp Neurol. 2018 Mar;301(Pt A):1-12
pubmed: 29262292
Eur J Neurol. 2010 Apr;17(4):541-9
pubmed: 19961535
Nat Rev Neurol. 2018 Feb;14(2):94-105
pubmed: 29302065
Hum Mol Genet. 2000 Mar 22;9(5):787-93
pubmed: 10749986
J Neurosci. 2006 Nov 15;26(46):12089-99
pubmed: 17108182
FASEB J. 2009 Mar;23(3):957-66
pubmed: 19028838
J Clin Invest. 2017 Oct 2;127(10):3577-3587
pubmed: 28872464
Front Cell Dev Biol. 2019 Mar 20;7:41
pubmed: 30949481
Sci Rep. 2017 Nov 15;7(1):15678
pubmed: 29142250
J Neurosci. 2002 Aug 1;22(15):6696-703
pubmed: 12151548
Neurol Genet. 2018 Dec 07;4(6):e292
pubmed: 30697589
Adv Biol Regul. 2018 Jan;67:1-6
pubmed: 29102395
FASEB J. 2014 Sep;28(9):3906-18
pubmed: 24858279
Arch Neurol. 1988 Sep;45(9):1004-8
pubmed: 3415518
Brain Res Bull. 2015 Aug;117:24-31
pubmed: 26189928
Methods Cell Biol. 2010;98:337-57
pubmed: 20816241
Cell Death Differ. 2004 Feb;11(2):196-202
pubmed: 14576772
EMBO J. 2012 Mar 7;31(5):1080-94
pubmed: 22246186
J Neuropathol Exp Neurol. 2006 Sep;65(9):914-29
pubmed: 16957585
Mult Scler Relat Disord. 2017 Oct;17:230-233
pubmed: 29055464
Hum Mol Genet. 2015 Jun 1;24(11):3143-54
pubmed: 25701871
Nucleus. 2016 Nov;7(6):547-553
pubmed: 27854160
Exp Neurol. 2016 Sep;283(Pt B):452-75
pubmed: 27068622
Exp Neurol. 1997 Sep;147(1):1-9
pubmed: 9294397
N Engl J Med. 1984 Oct 11;311(15):948-53
pubmed: 6472420
Cancer Cell Microenviron. 2015;2(3):
pubmed: 26807429
Glia. 2018 Apr;66(4):693-707
pubmed: 29210103
Front Mol Neurosci. 2017 Jul 18;10:215
pubmed: 28769756
Brain. 2019 Jul 1;142(7):1905-1920
pubmed: 31143934
J Cell Biol. 2013 Mar 4;200(5):605-17
pubmed: 23439683
Nat Genet. 2006 Oct;38(10):1114-23
pubmed: 16951681
Hum Mol Genet. 2015 May 15;24(10):2746-56
pubmed: 25637521
Adv Exp Med Biol. 2014;773:415-30
pubmed: 24563359
J Immunol. 1994 May 15;152(10):5022-31
pubmed: 8176220
J Neuropathol Exp Neurol. 2013 Nov;72(11):1090-103
pubmed: 24128683
J Clin Invest. 2017 Sep 1;127(9):3271-3280
pubmed: 28862639
Nucleus. 2015;6(1):8-14
pubmed: 25602590
Ann Neurol. 2015 Sep;78(3):412-25
pubmed: 26053668
Glia. 2006 May;53(7):696-703
pubmed: 16498619
Auton Neurosci. 2016 Feb;195:20-6
pubmed: 26896090
J Lipid Res. 2019 Feb;60(2):312-317
pubmed: 30287524
Neurol Genet. 2019 Jan 24;5(1):e305
pubmed: 30842973
Cell Tissue Res. 2015 Jun;360(3):621-31
pubmed: 25532872
Nat Med. 2002 Jun;8(6):613-9
pubmed: 12042813
Transl Neurodegener. 2014 Feb 05;3(1):4
pubmed: 24495672
Neuron. 2006 Mar 16;49(6):823-32
pubmed: 16543131
J Neuroimmunol. 2008 Nov 15;204(1-2):52-7
pubmed: 18771807
Front Neurosci. 2019 Oct 21;13:1030
pubmed: 31695592
Mol Biol Cell. 2016 Jan 1;27(1):35-47
pubmed: 26510501
Biochim Biophys Acta. 2013 Mar;1832(3):411-20
pubmed: 23261988
Cell Mol Neurobiol. 2017 Jan;37(1):1-4
pubmed: 26935061
Biomaterials. 2015 Jul;56:78-85
pubmed: 25934281
Curr Opin Cell Biol. 2019 Jun;58:76-84
pubmed: 30889417
Auton Neurosci. 2011 Jan 20;159(1-2):123-6
pubmed: 20719577
Hum Mutat. 2013 Aug;34(8):1160-71
pubmed: 23649844

Auteurs

Stefano Ratti (S)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Isabella Rusciano (I)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Sara Mongiorgi (S)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Eric Owusu Obeng (E)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Alessandra Cappellini (A)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Gabriella Teti (G)

Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Via Irnerio 48, Bologna, Italy.

Mirella Falconi (M)

Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Via Irnerio 48, Bologna, Italy.

Lia Talozzi (L)

Functional MR Unit, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Sabina Capellari (S)

Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC NeuroMet, Bologna, Italy.

Anna Bartoletti-Stella (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC NeuroMet, Bologna, Italy.

Pietro Guaraldi (P)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC NeuroMet, Bologna, Italy.

Pietro Cortelli (P)

Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC NeuroMet, Bologna, Italy.

Pann-Ghill Suh (PG)

Korea Brain Research Institute, Daegu, Republic of Korea.
School of Life Sciences, UNIST, Ulsan, Republic of Korea.

Lucio Cocco (L)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy. lucio.cocco@unibo.it.

Lucia Manzoli (L)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy. lucia.manzoli@unibo.it.

Giulia Ramazzotti (G)

Cellular Signalling Laboratory, Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH